David Arkowitz - 27 Apr 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Reporting relationship: Chief Financial Officer
Issuer ticker: MCRB
Reported as of: 27 Apr 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 May 2023, 16:43:22 UTC
Prior SEC filing: 14 Apr 2023
Next SEC filing: 31 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz

Key filing fact

David Arkowitz filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 01 May 2023.

Key facts

This page summarizes David Arkowitz's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 May 2023, 16:43.

Change

Previous filing in this sequence was filed on 14 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MCRB transaction

Common stock

Award

Transaction value: $0
Shares: +42,500
Change %: +34%
Price: $0.000000
Shares after: 166,613
Date: 27 Apr 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On November 23, 2021, the reporting person was granted an award of 85,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 42,500 shares.

Footnote F2

Includes 11,121 shares of common stock acquired under the Issuer's employee stock purchase plan.